More than 2 million adverse event and medication error reports are evaluated by the FDA’s Office of Surveillance and Epidemiology every year, showing why accurate safety assessments remain critical in pharmacovigilance.
Therefore, causality assessment in pharmacovigilance helps professionals determine how strongly an adverse drug reaction may be linked to a medicine using evidence such as temporal relationship, dechallenge, rechallenge, and alternative causes. Moreover, structured approaches like WHO-UMC and Naranjo support consistent ICSR evaluation, documentation, and regulatory decision-making. Understanding these frameworks helps PV teams create defensible assessments and improve patient safety monitoring.
Table of Contents
What Is Causality Assessment in Pharmacovigilance?
Causality assessment in pharmacovigilance is a structured process used to evaluate whether available clinical evidence supports a possible relationship between a medicinal product and an adverse event. It considers factors such as temporal relationship, dechallenge, rechallenge, and alternative causes. Moreover, consistent assessment methods help PV teams document safety decisions, improve ICSR quality, and support reliable regulatory reporting.
Why Can a Causality Decision Become an Inspection Risk?
A causality decision can create regulatory risk when the assessment lacks clear evidence, consistent medical judgment, or complete documentation. Moreover, unsupported overrides, missing follow-up information, and weak rationale can affect the reliability of adverse drug reaction evaluations. Therefore, PV teams should apply structured causality assessment methods, document the reasoning behind decisions, and maintain traceable evidence to support ICSR quality and inspection readiness.
How Evidence Becomes a Defensible Causality Decision
A defensible causality decision depends on connecting clinical evidence, medical judgment, and documented reasoning. PV teams must evaluate available information carefully because tools such as WHO-UMC and the Naranjo Scale support assessment but do not replace expert review. Moreover, clear ICSR documentation helps demonstrate why a decision was made and supports consistent regulatory reporting.
The following topics explain how teams can apply causality frameworks, evaluate evidence quality, and maintain reliable safety decisions.
- Apply WHO-UMC Without Turning Categories Into Certainty (Available PDF)
- Use the Naranjo Scale as an Evidence Check, Not a Final Verdict (Available PDF)
- Make the ICSR Evidence Support the Causality Decision (Available PDF)
- Know When Causality Changes Regulatory Reporting (Available PDF)
This infographic shows the causality decision pathway from drug exposure to evidence evaluation, assessment, and reporting, helping PV teams understand how structured decisions support reliable safety conclusions.
Apply WHO-UMC Without Turning Categories Into Certainty (Available PDF)
The WHO-UMC system provides structured causality categories for adverse drug reactions. These categories support expert evaluation with clinical evidence and professional judgment.
Download The Use of the WHO-UMC System for Standardised Case Causality Assessment Here
Use the Naranjo Scale as an Evidence Check, Not a Final Verdict (Available PDF)
The Naranjo Scale uses scoring questions to estimate adverse drug reaction likelihood. It supports assessment but does not replace clinical review.
Download Naranjo Adverse Drug Reaction Probability Scale Here
Make the ICSR Evidence Support the Causality Decision (Available PDF)
A strong causality decision requires complete ICSR evidence, including clinical details and follow-up information. Clear documentation supports reliable PV decisions and safety reporting.
Know When Causality Changes Regulatory Reporting (Available PDF)
Causality assessment can affect regulatory reporting decisions. Teams should document the rationale and follow pharmacovigilance requirements.
Which Evidence Should Carry the Most Weight in Causality Assessment?
A reliable causality assessment depends on evaluating the strength, consistency, and completeness of available evidence. PV teams should consider factors such as temporal relationship, dechallenge, rechallenge, biological plausibility, and alternative causes before reaching a conclusion. Moreover, documenting how each evidence factor influences the decision helps create transparent and defensible safety assessments.
The table below compares key evidence factors that can strengthen, weaken, or create uncertainty in a suspected drug-event relationship.
| Evidence Factor | How It Strengthens Causality | How It Weakens or Creates Uncertainty | Documentation Expectation |
|---|---|---|---|
|
Temporal Relationship |
The adverse event occurs after drug exposure within a biologically reasonable timeframe. |
The timing does not match known drug effects or expected latency. |
Record treatment start date, event onset, and timeline assessment. |
|
Dechallenge |
The event improves or resolves after stopping the suspected medicine. |
The event continues despite withdrawal or improvement is unrelated to treatment changes. |
Document treatment interruption, clinical outcome, and interpretation. |
|
Rechallenge |
The event reappears after re-exposure to the medicine, supporting a stronger association. |
No recurrence occurs after re-exposure or rechallenge is not clinically relevant. |
Record rechallenge details, outcome, and risk considerations. |
|
Alternative Causes |
Few other explanations exist for the adverse event. |
Other diseases, medicines, or patient factors provide possible explanations. |
Assess competing causes and explain their impact on the final decision. |
This infographic compares WHO-UMC and Naranjo approaches to show how different causality assessment methods interpret the same adverse drug reaction evidence.
How Should Teams Control Causality Reassessment and Overrides?
Pharmacovigilance teams should manage causality reassessment through clear governance, documented medical review, and traceable decision-making. New follow-up information, expert disagreement, or revised clinical evidence may justify a changed assessment; however, every override should record what changed, who approved it, and why. This approach helps maintain consistency, supports data integrity, and ensures that updated causality decisions remain defensible during audits and inspections.
Final Words
As pharmacovigilance systems become more complex, regulatory expectations continue to focus on traceable evidence, consistent medical review, and documented decision-making. According to the EMA Pharmacovigilance Inspectors Working Group annual report, 87 deficiencies were identified during CHMP-requested pharmacovigilance inspections, including 29 major findings (33.33%) and 58 minor findings (66.67%), highlighting the continued importance of robust safety systems and inspection readiness. Therefore, effective causality assessment in pharmacovigilance helps teams maintain defensible safety decisions, improve reporting quality, and support compliance with evolving regulatory expectations.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
Teams justify causality assessments by maintaining documented evidence, medical rationale, case evaluation history, and clear links between ICSR information and the final decision.
Yes. Causality can be reassessed when new follow-up data, medical review, or additional evidence becomes available. The reason, approval, and impact of the change should be documented.
Key evidence includes temporal relationship, dechallenge, rechallenge, alternative causes, clinical findings, and complete ICSR documentation. These factors help support a consistent and defensible causality decision.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.